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Background:  Helicobacter pylori (H. pylori) infection in gastric mucosa may cause systemic inflammatory 
reaction. This study aimed to examine the association between the infection and serum high sensitivity C-reactive 
protein (hsCRP). 
Methods: Subjects were comprised of three groups; 453 health checkup examinees from Yakumo town inhabi-
tants in Hokkaido, Japan (YTI, 153 males and 300 females), 449 health checkup examinees (ENUH, 273 males 
and 176 females), and 255 female patients of an infertility clinic (PIC), Nagoya University Hospital. Twenty par-
ticipants with hsCRP more than 1 mg/dl were excluded from the analysis. Those with hsCRP more than 0.1mg/dl 
were defined as high hsCRP individuals. H. pylori infection status was examined with a serum IgG antibody test. 
Results: When the three groups were combined, the geometric mean of hsCRP concentration was significantly 
higher among the seropositives (0.047mg/dl) than among the seronegatives (0.035mg/dl); p＜0.0001 by a t-test. 
The percentage of high hsCRP individuals was also higher in the seropositives than in the seronegatives among 
any group; 23.3% and 20.1% in YTI, 22.0% and 16.0% in ENUH, and 32.7% and 18.7% in PIC, respectively, al-
though the difference was significant only in ENUH. The summary odds ratio of the high hsCRP for the seroposi-
tives relative to the seronegatives was 1.38 (95% confidence interval, 1.01-1.89), when age, sex, body mass index, 
smoking, and subject group were adjusted by a logistic model. 
Conclusions: In three groups, hsCRP was higher among the infected individuals. The summary odd ratio indi-
cated that H. pylori infection could influence the serum hsCRP level. 
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1. Introduction 
Helicobacter pylori (H. pylori)  is a spiral-shaped, 
gram-negative bacterium that inhabits the stomach 
mucosa in more than 50% of Japanese adults, and fur-
ther more from child to elderly in developing countries 
[1]. This bacterium can elicit lifelong inflammatory and 
immune responses with release of various bacterial 
and host-dependent cytotoxic substances [2], resulting 
in chronic gastritis, peptic ulcer, and gastric cancer [3].   
Epidemiological studies have suggested that H. 
pylori infection might be involved in the pathogenesis 
of coronary heart disease [4-6]. The suspicion about H. 
pylori involvement in the pathological lesions is based 
on the following: (i) local inflammation can have sys-
temic effects; (ii) H. pylori gastric infection is a chronic 
process that lasts for decades; and (iii) persistent in-
fection induces chronic inflammatory and immune 
responses that can induce lesions both local and re-
mote sites from the primary infection site [7, 8]. The Int. J. Med. Sci. 2008, 5 
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manifestation may be caused by potential mechanisms 
with direct or indirect actions [9]. The direct effects on 
the vascular wall could include endothelial injury and 
dysfunction through circulating endotoxins, smooth 
muscle proliferation, and local inflammation. The in-
direct effects are more often pronounced, including 
elevation of inflammatory mediators with proinflam-
matory, procoagulant, and atherogenic action, pro-
duction of cross-reactive antibodies, as well as nutri-
ent/vitamin malabsorption and metabolic distur-
bances such as overproduction of ammonia by the 
bacterium. 
C-reactive protein (CRP) is an acute-phase reac-
tant that originates from the liver. CRP has many 
clinical and biological effects and can be used for the 
diagnosis and follow-up of various inflammatory and 
traumatic processes [10]. There is strong evidence that 
CRP is a powerful predictor of incident cardiovascular 
events independent of levels of LDL cholesterol, all 
levels of the Framingham risk score, and the metabolic 
syndrome [11-19]. The basal CRP level in individuals 
free from acute illness is reproducible [20]. Its deter-
minants reportedly include age and smoking [21], 
while substantial heritability (35–40%) was also re-
ported in familial aggregation studies [22].   
Examining the association between H. pylori in-
fection and serum CRP levels seemed important to 
elucidate the relevance of H. pylori infection with 
coronary heart disease, especially atherosclerosis. The 
previous studies on the association, however, pro-
vided inconsistent results [23, 24]. This study aimed to 
examine the association in three different Japanese 
groups. 
2. Subjects and methods 
Study subjects 
The first group (YTI) was 524 apparently healthy 
inhabitants, who attended a health check-up at Ya-
kumo town, Hokkaido, Japan in 2006. Among them, 
505 agreed to participate in the study with written 
informed consent. Lifestyle data collected with a 
self-administered questionnaire, as well as residual 
blood samples, were available from 459 subjects. Six 
subjects with serum high-sensitivity CRP (hsCRP) > 1 
mg/dl were excluded from the analysis, because they 
might have an inflammatory disease. Remaining 453 
subjects (153 males and 300 females) aged from 39 to 90 
years were used for the present study.  
The second group (ENUH) incorporated health 
checkup examinees at Department of Clinical Preven-
tive Medicine, Nagoya University Hospital, who vis-
ited the department between June 2003 and February 
2004. After the explanation of the study, 476 agreed 
lifestyle questionnaire and donation of 7ml peripheral 
blood for research purposes. Among them, 453 sub-
jects could determine the presence of H. pylori infection 
and measure the hsCRP. Those with hsCRP more than 
1 mg/dl were also excluded, remaining 449 subjects 
(273 males and 176 females) aged from 17 to 89 years 
for the present study.  
The third group (PIC) consisted of 264 female pa-
tients at an infertility clinic, who underwent treatment 
for infertility at Department of Obstetrics and Gyne-
cology or Department of Maternal and Perinatal 
Medicine, Nagoya University Hospital between Feb-
ruary 2001 and December 2004. Stored blood samples 
of the patients were available for research purposes. 
Those with hsCRP more than 1 mg/dl were similarly 
excluded, remaining 255 females aged from 21 to 48 
years. All the three studies were approved by the Eth-
ics Committee of Nagoya University School of Medi-
cine (approval number 398, 52, 278 for YTI, ENUH and 
PIC, respectively). 
Determination of serum H. pylori infection and hsCRP 
value 
Sera were separated from blood samples imme-
diately after blood draw. They were kept in a deep 
freezer at -80 ºC until analyses. A commercially avail-
able direct ELISA kit (“E Plate ‘Eiken’ H. pylori Anti-
body” from Eiken Kagaku, Tokyo, Japan) was used to 
determine the presence of H. pylori infection. The 
seropositive was defined as H. pylori IgG antibody 
more than 10 U/ml. The hsCRP was measured with a 
particle-enhanced immunoturbidometric latex agglu-
tination assay by SRL Co. Ltd., Tokyo. The assay could 
detect 0.004 mg/dl of CRP. Undetectable CRP values 
were recorded as 0.002 mg/dl. The staff in the labora-
tory was blinded to the seropositivity of H. pylori an-
tibody. 
Statistical analysis 
The difference in geometric mean of serum 
hsCRP between H. pylori positive subjects and negative 
subjects was statistically tested with a t-test, because 
loge-transformed hsCRP distributed symmetrically 
with one peak. Participants with hsCRP more than 0.1 
mg/dl were defined as high hsCRP individuals in this 
study. The proportion of high hsCRP subjects was 
compared between the seropositives and the sero-
negatives with a Fisher’s exact test. Odds ratios (ORs) 
and 95% confidence intervals (CIs) of the seropositives 
compared with the seronegatives for high hsCRP were 
calculated using unconditional logistic regression 
models, adjusting for age (<30, 30-39, 40-49, 50-59, 
60-69, or  ≧70 years), sex, body mass index (BMI) (<25, 
or  ≧25kg/m2), smoking (never, former, current, or 
unknown), and study group. The heterogeneity in the 
OR among study groups was tested with the Q statis-Int. J. Med. Sci. 2008, 5 
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tic. The data were analyzed by the statistical software 
“STATA/SE version 9.0” (College Station, TX, USA).  
3. Results 
The sex, age, hsCRP level, BMI, and smoking 
habits of the participants according to the study group 
are summarized in Table 1. In YTI, females were 
dominant (66.2%), and 65.3% were participants aged 
60 years or older. In ENUH, males were dominant 
(60.8%), and age was distributed over a wider range. 
PIC was the group of only females aged under 50 
years, because they were sampled from patients of an 
infertility clinic. The hsCRP distributed from unde-
tectable level close to 1 mg/dl in any group, and the 
frequency of high hsCRP individuals was comparable 
among the three groups. The prevalence of H. pylori 
infection in YTI was 62.1% (95/153) in males and 54.7% 
(164/300) in females, 39.9% (109/273) and 36.9% 
(65/176) in ENUH, respectively, and 20.4% (52/255) in 
PIC. In total, the prevalence was 47.9% (204/426) in 
males and 38.4% (281/731) in females.    
Table 1 Characteristics of subjects from three study groups 
   YTI*  ENUH† PIC‡ Total 
Characteristics (n=453) (n=449) (n=255)  (n=1,157) 
Sex      
Males  153 (33.8)  273 (60.8)  0 ( 0.0) 426 (36.8)
Females  300 (66.2)  176 (39.2)  255 (100.0) 731 (63.2)
Age (years)      
19-29 0  ( 0.0) 19  ( 4.2)  53 (20.8) 72 ( 6.2)
30-39 5  ( 1.1)  97 (21.6)  177 (69.4) 279 (24.1)
40-49 34  ( 7.5)  111 (24.7)  25 ( 9.8) 170 (14.7)
50-59  118 (26.0)  116 (25.8)  0 ( 0.0) 234 (20.2)
60-69  171 (37.7)  80 (17.8)  0 ( 0.0) 251 (21.7)
≧70  125 (27.6)  26 ( 5.8)  0 ( 0.0) 151 (13.1)
BMI (kg/m2)      
＜25  296 (65.3)  358 (79.7)  0 ( 0.0) 654 (56.5)
≧25  157 (34.7)  91 (20.3)  0 ( 0.0) 248 (21.4)
Unknown   0 ( 0.0) 0  ( 0.0)  255 (100.0) 255 (22.1)
hsCRP (mg/dl)      
≦0.1  354 (78.1)  370 (82.4)  200 (78.4) 924 (79.9)
＞0.1  99 (21.9)  79 (17.6)  55 (21.6) 233 (20.1)
Geometric  mean  0.047 0.038 0.038 0.040
1st-3rd quartile  0.022-0.090  0.019-0.072 0.011-0.076 0.018-0.082
Range  0.002-0.973 0.002-0.923 0.002-0.994 0.002-0.994
Smoking      
Never  280 (61.8)  230(51.2)  0 ( 0.0) 510 (56.7)
Former  97 (21.4)  126 (28.1)  0 ( 0.0) 223 (24.8)
Current  76 (16.8)  91 (20.3)  0 ( 0.0) 167 (18.6)
Unknown   0 ( 0.0) 2  ( 0.5)  255 (100.0) 257 (22.2)
YTI*: Yakumo Town Inhabitants, ENUH†: Examinees of Nagoya 
University Hospital, PIC‡: Patients of Infertility Clinic, Nagoya Uni-
versity Hospital. 
Percentages are shown in parentheses. 
 
Table 2 shows associations of categorized hsCRP (
≦0.1 mg/dl or ＞0.1 mg/dl) with background factors. 
In YTI, ENUH and whole participants, no significant 
difference was found in the prevalence of hsCRP be-
tween sexes, although the high hsCRP was more 
prevalent in males of YTI and in females of ENUH. 
There was no significant difference in the hsCRP level 
across age groups. The geometric mean of hsCRP level 
was 0.051 mg/dl for H. pylori positive  subjects and 
0.042 mg/dl for H. pylori negative subjects in YTI, 0.043 
mg/dl and 0.036 mg/dl in ENUH, 0.045 mg/dl and 
0.028 mg/dl in PIC, respectively. Corresponding 
1st-3rd quartile was 0.025-0.094 and 0.020-0.082 in YTI, 
0.023-0.072 and 0.018-0.071 in ENUH, and 0.016-0.143 
and 0.010-0.061 in PIC. In total, the geometric mean of 
hsCRP level was 0.047mg/dl for H. pylori positive 
subjects and 0.035mg/dl for H. pylori negative subjects, 
with the 1st-3rd quartile of 0.023-0.093 and 0.015-0.073, 
respectively. The hsCRP geometric mean was signifi-
cantly higher in subjects with H. pylori positive subjects 
than in those without (p＜0.0001 by a t-test). 
In PIC, the high hsCRP level was observed more 
frequently among subjects with H. pylori infection than 
among those without it, with a statistically significant 
difference; 32.7% vs. 18.7%, p=0.037 (Table 3). A simi-
lar difference in the prevalence of high hsCRP level 
was also detected in the pooled population (23.5% vs. 
17.7%, p=0.017). In YTI and ENUH groups, the pro-
portion of high hsCRP level was similarly higher in 
those with H. pylori infection compared with those 
without it, but the difference was not significant; 
p=0.491 for YTI and p=0.127 for ENUH.  
Table 3 also shows OR and 95% CI of H. pylori 
seropositivity for the high hsCRP. The ORs were 1.18 
(95% CI, 0.74-1.90) in TYI, 1.37 (95% CI, 0.81-2.31) in 
ENUH, and 2.20 (95% CI, 1.11-4.37) in PIC, after ad-
justment for age, sex, BMI, and smoking habits. The Q 
test for heterogeneity showed the differences in the OR 
among the three groups was not significant (p=0.337). 
The summary OR was 1.38 (95% CI, 1.01-1.89), with 
allowance for study groups; 1.20 (95% CI, 0.73-1.95) in 
males and 1.61 (95% CI, 1.09-1.38) in females. Because 
the median of the age in pooled data was 52, we di-
vided the data into two groups at the age; the younger 
group (age≦52 years) and the older group (age>52 
years). The summary OR of the younger group ad-
justed for sex, BMI, smoking, and subject groups was 
1.60 (95% CI, 1.00-2.55), while the corresponding OR of 
the older group was 1.27 (95% CI, 0.85-1.90).  
 Int. J. Med. Sci. 2008, 5 
 
227
Table 2 Associations between the serum level of hsCRP and background factors 
   YTI*    ENUH†   PIC‡   Total 
  (n=453)    (n=449)   (n=255)   (n=1,157) 
Characteristics Low§ High
‖   Low§ High
‖   Low§ High
‖   Low§ High
‖ 
Sex          
Males   111 (72.5)  42 (27.5)    228 (83.5) 45 (16.5) 0 ( 0.0) 0 ( 0.0)    339 (79.6) 87 (20.4)
Females  243 (81.0)  57 (19.0)    142 (80.7) 34 (19.3) 200 (78.4) 55 (21.6)    585 (80.0) 146 (20.0)
p-value¶ 0.054    0.449    -    0.879 
Age (year)          
19-29  0 ( 0.0)  0 ( 0.0)    17 (89.5) 2 (10.5) 39 (73.6) 14 (26.4)    56 (77.8) 16 (22.2)
30-39  5 (100.0)  0 ( 0.0)    82 (84.5) 15 (15.3) 140 (79.1) 37 (20.9)    227 (81.4) 52 (18.6)
40-49 29  ( 85.3)  5 (14.7)    94 (84.7) 17 (15.3) 21 (84.0) 4 (16.0)    144 (84.7) 26 (15.3)
50-59 97  ( 82.2)  21 (17.8)    93 (80.2) 23 (19.8) 0 ( 0.0) 0 ( 0.0)    190 (81.2) 44 (18.8)
60-69 130  ( 76.0)  41 (24.0)    63 (78.8) 17 (21.2) 0 ( 0.0) 0 ( 0.0)    193 (76.9) 58 (23.1)
≧70 93  ( 74.4)  32 (25.6)    21 (80.8) 5 (19.2) 0 ( 0.0) 0 ( 0.0)    114 (75.5) 37 (24.5)
p-value¶  0.371    0.793   0.575   0.255 
BMI (kg/m2)          
＜25  249 (84.1)  47 (15.9)    302 (84.4) 56 (15.6) 0 ( 0.0) 0 ( 0.0)    551 (84.3) 103 (15.8)
≧25  105 (66.9)  52 (33.1)    68 (74.7) 23 (25.3) 0 ( 0.0) 0 ( 0.0)    173 (69.8) 75 (30.2)
Unknown   0 ( 0.0)  0 ( 0.0)    0 ( 0.0) 0 ( 0.0) 200 (78.4) 55 (21.6)    200 (78.4) 55 (21.6)
p-value¶ <0.001    0.044    -    <0.001 
Smoking          
Never  225 (80.4)  55 (19.6)    190 (82.6) 40 (17.4) 0 ( 0.0) 0 ( 0.0)    415 (81.4) 95 (18.6)
Former  73 (75.3)  24 (24.7)    103 (81.8) 23 (18.3) 0 ( 0.0) 0 ( 0.0)    176 (78.9) 47 (21.1)
Current  56 (73.7)  20 (26.3)    75 (82.4) 16 (17.6) 0 ( 0.0) 0 ( 0.0)    131 (78.4) 36 (21.6)
Unknown 0  ( 0.0) 0  ( 0.0)    2 (100.0) 0 ( 0.0) 200 (78.4) 55 (21.6)    202 (78.6) 55 (21.4)
p-value¶ 0.324    0.990    -    0.589 
Total  354 (78.1)  99 (21.9)    370 (82.4) 79 (17.6) 200 (78.4) 55 (21.6)    924 (79.8) 233 (20.1)
YTI*: Yakumo Town Inhabitants, ENUH†: Examinees of Nagoya University Hospital, PIC‡: Patient of Infertility Clinic, Nagoya Unversity 
Hospital, Low
§: hsCRP≦0.1mg/dl, High
‖: hsCRP>0.1mg/dl, and p-value
¶: Fisher’s exact test. 
Percentages are shown in parentheses. 
Table 3 Associations of the serum level of hsCRP with H. pylori seropositivity and odds ratio (OR) and 95% confidence interval 
(CI) of H. pylori for hsCRP 
  H. pylori Low* High
† OR  (95%  CI)  aOR
‡ (95% CI)  aOR
§ (95% CI) 
YTI
‖   Seronegative  155 (79.9)  39 (20.1) 1 [Reference] 1 [Reference]  1 [Reference]
n=453  Seropositive  199 (76.8)  60 (23.2) 1.20 [ 0.76-1.89] 1.13 [ 0.71-1.79]  1.18 [ 0.74-1.90]
ENUH
¶  Seronegative  220 (84.0)  42 (16.0) 1 [Reference] 1 [Reference]  1 [Reference]
n=449  Seropositive  131 (78.0)  37 (22.0) 1.49 [ 0.92-2.44] 1.38 [ 0.83-2.32]  1.37 [ 0.81-2.31]
PIC**  Seronegative  165 (81.4)  38 (18.7) 1 [Reference] 1 [Reference]  1 [Reference]
n=255  Seropositive   35 (67.3)  17 (32.7) 2.11 [ 1.07-4.16] 2.20 [ 1.11-4.37]  -
Pooled
††  Seronegative  553 (82.3)  119 (17.7) 1 [Reference] 1 [Reference]  1 [Reference]
n=1,157  Seropositive  371 (76.5)  114 (23.5) 1.45 [ 1.07-1.97] 1.37 [ 1.01-1.86]  1.38 [ 1.01-1.89]
Low*: hsCRP≦0.1mg/dl, High†: hsCRP>0.1mg/dl, ‡Sex-, and age-adjusted odds ratios (aOR‡), §Sex-, age- smoking- and BMI-adjusted odds 
ratios (aOR§), YTI
‖: Yakumo Town Inhabitants, ENUH¶: Examinees of Nagoya University Hospital, PIC**: Patients of Infertility Clinic, Nagoya 
University Hospital, Pooled††: three studies were combined, and the ORs were adjusted additionally for the study groups using dummy 
variables. 
Percentages are shown in parentheses. 
 
4. Discussion 
The present paper examined the association of H. 
pylori seropositivity with hsCRP in the range of 0.002 to 
1.0 mg/dl, based on three different Japanese groups 
with 1,157 subjects in total. Although the background 
of the three groups was different, the sex, age, BMI, 
and smoking adjusted OR of the seropositive for 
hsCRP > 0.1 mg/dl relative to hsCRP ≦ 0.1 mg/dl 
was larger than unity in all three groups. The sum-
mary OR was 1.38 (95% CI, 1.01-1.89), indicating that 
H. pylori seropositivity was associated with a higher 
hsCRP among those with hsCRP ≦ 1 mg/dl. We 
tested the heterogeneity of the OR for high CRP levels 
in relation to the seropositivity among three groups. 
Because no significant differences in the OR were 
found among study groups, we pooled the data de-
rived from three different populations. 
Although  H. pylori infection is associated with 
coronary artery disease, the pathway to elevate the 
disease risk is not clear. There are several possibilities 
for the mechanism underlying a causal role of H. pylori Int. J. Med. Sci. 2008, 5 
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infection in endothelial dysfunction. First, H. pylori 
may have the direct effect on the structure and func-
tion of vascular endothelial cells. Extract of H. pylori 
has been reported to induce a disturbance of prolifera-
tion and apoptosis and to decrease viability of cultured 
vascular endothelial cells [25]. The second possibility is 
the nutritional effect of H. pylori [26]. An infection from 
H. pylori may cause malabsorption of folate, vitamin 
B6, and vitamin B12. This nutritional defect could lead 
to failure of methylation by 5-methyl-tetrahydrofolic 
acid and subsequent hyperhomocysteinanemia, which 
is toxic to endothelial cells. In our past study, serum 
folate was examined as a molecule connecting H. pylori 
infection with systemic diseases, resulting in no asso-
ciation between the seropositivity and serum folate 
[27]. CRP is also one of the candidate molecules, but 
there were limited reports on the association with H. 
pylori infection.  
A study on the effects of H. pylori eradication 
among 78 patients in Turkey reported that serum CRP 
was significantly reduced among 57 participants with 
successful eradication, but not among 21 participants 
in whom the eradication failed [23]. Another study 
r e p o r t e d  t h a t  i n c r e a s i n g  a g e ,  s m o k i n g ,  s y m p t o m s  o f  
chronic bronchitis, H. pylori and Chlamydia pneumo-
niae infections, and BMI were all associated with 
raised concentrations of CRP [24]. The present study 
demonstrated that H. pylori infection may slightly ele-
vate serum CRP, thereby may increase systemic dis-
ease risk. 
CRP is an easily measurable substance in blood. 
Increased levels of this protein indicate acute inflam-
mation. Many studies have shown that high levels of 
CRP also indicate an increased risk of suffering from a 
heart attack or stroke. The CRP test is not specific, and 
the levels fluctuate daily and throughout the day. The 
levels increase as a result of numerous factors includ-
ing aging, alcohol use, smoking, eating a high protein 
diet, coffee consumption, low levels of physical activ-
ity, chronic fatigue, high blood pressure, BMI, high 
triglycerides, rheumatoid arthritis, rheumatic fever, 
insulin resistance and diabetes [28], as well as heart 
attack. Medicines containing estrogen (oral contracep-
tive and hormone replacement therapy) may also ele-
vate CRP levels. In this study, we took factors, sex, age, 
BMI, and smoking into account, although information 
on BMI and smoking was not available for PIC group. 
Among the female subjects, smokers and fatty ladies 
were relatively rare. 
The present study has several limitations. First, H. 
pylori infection was determined by only serum anti-
body, not by the other diagnosis methods with a 
higher sensitivity and specificity, such as a urease 
breath test. Since the present analysis was based on 
stored blood samples from multi-purpose studies, al-
ternative methods could not be applied for the detec-
tion of H. pylori infection. Second, the information on 
the other factors that affect serum CRP level was not 
available. For example, chronic infections other than H. 
pylori could confound the association with H. pylori 
infection, since it seemed plausible that H. pylori in-
fected individuals might be vulnerable to other infec-
tions which elevate CRP. The adjustments of the po-
tential confounding factors might not be enough to 
confirm the association with H. pylori infection. Third, 
this study was a cross-sectional study so that the 
causal inference was not possible directly. Finally, the 
effects of medication on CRP were not removed. Since 
several drugs, such as statins, were reported to influ-
ence CRP levels [29, 30], the adjustment for such 
medications could allow clear interpretation on the 
observed association.   
If H. pylori has effects on the function of vascular 
endothelial cells, serum CRP could be one of the 
molecules to connect both. H. pylori infection stimu-
lates the production of proinflammatory cytokines 
such as tumor necrosis factor (TNF), interleukin (IL) -6, 
and IL-8 [31, 32]. H. pylori was detected not only in 
gastric mucosa but also in human atherosclerotic 
plaque [33, 34], and the expression of intercellular ad-
hension molecule-1 was higher in plaques containing 
H. pylori than in those without it [33]. The production 
of CRP is regulated by cytokines, principally inter-
leukins [35, 36], whose effects are modified by other 
cytokines and growth factors [37], as well as by hor-
mones such as cortisol and insulin [38]. Production of 
cytokines and stress hormones may be altered in con-
ditions other than inflammation or injury. TNF-α is a 
potent inducer of IL-6 by various cells. Therefore, the 
association of CRP concentration with H. pylori infec-
tion could be explained by the actions of cytokines, 
hormones, or both.  
In conclusion, the present cross-sectional study 
based on the three different subjects showed a signifi-
cant association between H. pylori infection and serum 
hsCRP levels, supporting that H. pylori infection may 
increase the serum CRP. The possible attribution of H. 
pylori infection to CRP elevation could be a route to H. 
pylori negative subjects related coronary heart disease 
with the base of atherosclerosis. Since many factors 
influence the CRP levels, larger studies with informa-
tion on potential confounding factors are necessary to 
confirm the association. 
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